Amendment No. 1 to Schedule 13D for LAVA Therapeutics N.V.

This Amendment No. 1 to Schedule 13D, filed by Cooperatieve Gilde Healthcare IV U.A. and related entities, reports the sale of 174,678 common shares of LAVA Therapeutics N.V. between October 8, 2025, and October 13, 2025. The shares were sold in open market transactions at weighted average prices ranging from $1.5377 to $1.5727 per share, generating aggregate proceeds of approximately $271,019.51. The Reporting Persons, including Gilde Healthcare IV Management B.V. and Gilde Healthcare Holding B.V., collectively hold 5,246,492 common shares, representing approximately 19.9% of the outstanding shares as of August 8, 2025. The amendment also includes a joint filing agreement among the Reporting Persons.